AI-Driven Tumor Response Evaluation for Solid Tumors

计划入组 6,120 人 · 首次发布于 2026 年 7 月 6 日

Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors

计划入组 49 人 · 首次发布于 2011 年 4 月 26 日

Biomarker Study in Samples From Patients With Malignant Rhabdoid Tumor of the Kidney or Atypical Teratoid Rhabdoid Tumor

首次发布于 2011 年 10 月 17 日

tyrosine kinase modulators (Kyowa/Cephalon)

solid tumors therapy

C-4

Chongqing Genrix Biopharmaceutical Co., Ltd.

XUANZHUBIO-B

Context Therapeutics

United States

Pinetree Therapeutics Secures $47 Million Series B to Advance Novel Protein Degraders for Drug-Resistant Cancers

Avistone's ANS014004, a Novel c-Met Inhibitor, Advances in Phase I Trials for Solid Tumors

PAS-004 Shows Favorable Safety and Early Efficacy in MAPK-Driven Solid Tumors